// App-Quantinova.ai

: rFVIIIFc for First‐time Immune Tolerance Induction (ITI) Therapy: Interim Results from the Global, Prospective verITI‐8 Study

Researchers

Presenter

  • L. Malec

Principal Investigators

  • M. Carcao

  • N. Jain

  • M. Spasova

  • D. Konstantinov

  • N. Bhatnagar

  • A. Sharathkumar

  • N. Rodriguez

  • N. Hwang

  • A. Chan

  • M. Wang

  • A. Van Damme

  • J. Wright

  • S. Haya

  • E. Tsao

  • C. Reuter

  • S. Lethagen

  • F. Peyvandi

Medical Centers

  • Versiti Blood Center of Wisconsin, Milwaukee, WI, United States

  • Hospital for Sick Children, Toronto, ON, Canada

  • Sanofi, Waltham, MA, United States

  • University Multiprofile Hospital for Active Treatment ‘Sveti Georgi’, Department of Pediatrics, Plovdiv, Bulgaria

  • University Multiprofile Hospital for Active Treatment ‘Tsaritsa Yoanna ‐ ISUL’, Department for Treatment of Children with Oncohematological Diseases, Sofia, Bulgaria

  • Oxford Haemophilia and Thrombosis Centre, Children's Hospital Oxford, John Radcliffe Hospital, Oxford, United Kingdom

  • Stead Family Department of Pediatrics, Division of Hematology, Oncology and Stem Cell Transplantation, University of Iowa Stead Family Children's Hospital, Iowa City, IA, United States

  • Division of Pediatric Hematology, The University of Texas Health Science Center, Houston, TX, United States

  • Center for Inherited Blood Disorders, Orange, CA, United States

  • Pediatric Thrombosis and Hemostasis, McMaster Children's Hospital/Hamilton Health Sciences Foundation, Hamilton, Ontario, Canada

  • University of Colorado Hemophilia & Thrombosis Center, Aurora, United States

  • Division of Paediatric Haematology, Haemophilia Center, Saint‐Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium

  • Dayton Children's Hospital, Dayton, OH, United States

  • Hemostasis and Thrombosis Unit, Hematology Department, Hospital Universitari i Politecnic La Fe, Valencia, Spain

  • Sobi, Stockholm, Sweden

  • BRIC, Copenhagen University, Copenhagen, Denmark

  • Universit degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy

Locations

  • United States

  • Canada

  • Bulgaria

  • United Kingdom

  • Belgium

  • Spain

  • Sweden

  • Denmark

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Alpha-1-microglobulin/bikunin precursor

Drug/Treatment

  • FVIIIFc

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved